CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo

 
• By Cathy Kelly

Novartis exec discusses details around its agreements with CMS for outcomes based payments and indication-based pricing for Kymriah.

Money Wave

More from Pricing Debate

More from Market Access